NCT01065623View on ClinicalTrials.gov

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions

Neoplasms

Interventions

DRUG

BAY79-4620

1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities

Trial Locations (2)

3075 EA

Rotterdam

3584 CX

Utrecht

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY